Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC

Yohann Loriot; Morgan Rouprêt

doi:10.1016/S0007-4551(20)30278-2

Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC

Yohann Loriot, Morgan Rouprêt

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Local and systemic immunotherapies are used for the management of bladder cancer in daily practice. BCG has been administered for almost 40 years in patients with non-muscle invasive bladder cancer (NMIBC). Despite its efficacy, disease progression is observed in nearly 30% of patients. Given the antitumor activity of immune checkpoint inhibitors in metastatic setting, these therapies are currently investigated in NMIBC. Pembrolizumab is now approved by the Food and Drug Administration (FDA) for the treatment of patients with BCG-unresponsive, high-risk, NMIBC with carcinoma in situ with or without papillary tumors who are ineligible for or have not elected to undergo cystectomy. Several phase 3 trials are ongoing to investigate the efficacy of PD(L)1 inhibitors combined with BCG such as ALBAN study in France.

Translated title of the contribution	Immunothérapie des tumeurs de la vessie n'infiltrant pas le muscle: immunothérapies et TVNIM
Original language	English
Pages (from-to)	S49-S55
Journal	Bulletin du Cancer
Volume	107
Issue number	5
DOIs	https://doi.org/10.1016/S0007-4551(20)30278-2
Publication status	Published - 1 Jun 2020

Keywords

Immunotherapy
NMIBC
Urothelial carcinoma

Access to Document

10.1016/S0007-4551(20)30278-2

Cite this

@article{91e6506503e5414b9bba56d54072b857,

title = "Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC",

abstract = "Local and systemic immunotherapies are used for the management of bladder cancer in daily practice. BCG has been administered for almost 40 years in patients with non-muscle invasive bladder cancer (NMIBC). Despite its efficacy, disease progression is observed in nearly 30% of patients. Given the antitumor activity of immune checkpoint inhibitors in metastatic setting, these therapies are currently investigated in NMIBC. Pembrolizumab is now approved by the Food and Drug Administration (FDA) for the treatment of patients with BCG-unresponsive, high-risk, NMIBC with carcinoma in situ with or without papillary tumors who are ineligible for or have not elected to undergo cystectomy. Several phase 3 trials are ongoing to investigate the efficacy of PD(L)1 inhibitors combined with BCG such as ALBAN study in France.",

keywords = "Immunotherapy, NMIBC, Urothelial carcinoma",

author = "Yohann Loriot and Morgan Roupr{\^e}t",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Masson SAS",

year = "2020",

month = jun,

day = "1",

doi = "10.1016/S0007-4551(20)30278-2",

language = "English",

volume = "107",

pages = "S49--S55",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "5",

}

TY - JOUR

T1 - Immunotherapies in non-muscle invasive bladder cancer

T2 - immunotherapies and NMIBC

AU - Loriot, Yohann

AU - Rouprêt, Morgan

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Local and systemic immunotherapies are used for the management of bladder cancer in daily practice. BCG has been administered for almost 40 years in patients with non-muscle invasive bladder cancer (NMIBC). Despite its efficacy, disease progression is observed in nearly 30% of patients. Given the antitumor activity of immune checkpoint inhibitors in metastatic setting, these therapies are currently investigated in NMIBC. Pembrolizumab is now approved by the Food and Drug Administration (FDA) for the treatment of patients with BCG-unresponsive, high-risk, NMIBC with carcinoma in situ with or without papillary tumors who are ineligible for or have not elected to undergo cystectomy. Several phase 3 trials are ongoing to investigate the efficacy of PD(L)1 inhibitors combined with BCG such as ALBAN study in France.

AB - Local and systemic immunotherapies are used for the management of bladder cancer in daily practice. BCG has been administered for almost 40 years in patients with non-muscle invasive bladder cancer (NMIBC). Despite its efficacy, disease progression is observed in nearly 30% of patients. Given the antitumor activity of immune checkpoint inhibitors in metastatic setting, these therapies are currently investigated in NMIBC. Pembrolizumab is now approved by the Food and Drug Administration (FDA) for the treatment of patients with BCG-unresponsive, high-risk, NMIBC with carcinoma in situ with or without papillary tumors who are ineligible for or have not elected to undergo cystectomy. Several phase 3 trials are ongoing to investigate the efficacy of PD(L)1 inhibitors combined with BCG such as ALBAN study in France.

KW - Immunotherapy

KW - NMIBC

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85087155004&partnerID=8YFLogxK

U2 - 10.1016/S0007-4551(20)30278-2

DO - 10.1016/S0007-4551(20)30278-2

M3 - Article

C2 - 32620207

AN - SCOPUS:85087155004

SN - 0007-4551

VL - 107

SP - S49-S55

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 5

ER -

Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC

Abstract

Keywords

Access to Document

Other files and links

Cite this